- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| CURASIGHT Aktie jetzt für 0€ handeln | |||||
| Mo | Curasight reports early positive data from brain cancer treatment trial | 3 | Investing.com | ||
| Mo | Curasight Announces Encouraging Preliminary Data from Phase 1 Trial Evaluating First-in-Class Radiopharmaceutical uTREAT in High-Grade Gliomas | 202 | PR Newswire | Clear uptake of uTREAT in aggressive brain cancer (glioblastoma)Early data support the potential of first-in-class uPAR-targeted theranostic approach to enable more specific diagnosis and... ► Artikel lesen | |
| 05.01. | Curasight to hold Meetings in San Francisco During J.P. Morgan Healthcare Conference Week | 202 | PR Newswire | COPENHAGEN, Denmark, Jan. 5, 2026 /PRNewswire/ -- Curasight A/S ("Curasight" or "the Company" - (CPH: CURAS) a clinical-stage theranostic company focused on diagnosing and treating certain... ► Artikel lesen | |
| 29.12.25 | Curasight A/S resolves to issue a convertible loan note | 2 | Cision News | ||
| 29.12.25 | CURASIGHT: Resolutions of the Extraordinary General Meeting December 2025 | 4 | Cision News | ||
| 18.12.25 | Curasight: Erster Patient in Phase-1-Studie zu Hirntumor-Therapie behandelt | 3 | Investing.com Deutsch | ||
| 18.12.25 | Curasight doses first patient in phase 1 brain cancer treatment trial | 1 | Investing.com | ||
| 18.12.25 | Curasight Announces Successful Dosing of First Patient in Phase 1 trial with uTREAT in Brain Cancer | 323 | PR Newswire | Phase 1 trial in aggressive brain cancer (Glioblastoma) is the first clinical trial of uTREAT belonging to Curasight's treatment platformNo patient safety issues were reported The dosing... ► Artikel lesen | |
| 14.12.25 | CURASIGHT: Notice of Extraordinary General Meeting | 1 | Cision News | ||
| 12.12.25 | Curasight A/S has successfully completed a directed issue of shares of approximately DKK 16.4 million and has entered into a new loan facility | 3 | Cision News | ||
| 12.12.25 | Curasight A/S announces its intention to carry out a directed issue of shares and enter into a new loan facility | 1 | Cision News | ||
| 08.12.25 | XFRA NEW INSTRUMENTS AVAILABLE ON 08.12.2025 | 453 | Xetra Newsboard | The following instruments on XETRA do have their first trading 08.12.2025 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 08.12.2025
Aktien
1 KYG4600C1107 Hope Life International... ► Artikel lesen | |
| 28.11.25 | Curasight to present at HC Andersen Capital | 1 | Cision News | ||
| 27.11.25 | CURASIGHT: Interim report Q3 2025 | 2 | Cision News | ||
| 26.11.25 | Curasight's uTREAT Phase 1 Trial in Brain Cancer Now Open for Patient Enrollment | 243 | PR Newswire | Phase 1 study in aggressive brain cancer (Glioblastoma) is the first clinical trial investigation of uTREATSite given green light by European Medicines Agency (EMA) and is now open for patient... ► Artikel lesen | |
| 13.11.25 | Curasight to present at Dansk Aktionærforening InvestorDagen | 3 | Cision News | ||
| 29.10.25 | Curasight advances Phase 2 uTRACE prostate cancer trial with all European clinical sites in Part 2 now recruiting | 4 | Cision News | ||
| 01.10.25 | Curasight announces broadening and extension of patent protection for uTRACE | 1 | Cision News | ||
| 03.09.25 | Transaction with shares in Curasight A/S made by managerial employee | 1 | Cision News | ||
| 28.08.25 | CURASIGHT: Half-year report Q2 2025 | 1 | Cision News |
1 2 Weiter >>
24 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 72,35 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights | Announced Novartis agreement to acquire Avidity for total equity value of approximately $12 billion; Avidity expects to separate its early-stage precision cardiology... ► Artikel lesen | |
| BEAM THERAPEUTICS | 33,690 | +22,29 % | Beam Therapeutics Sets Strategic Priorities for its Genetic Disease and Hematology Franchises to Drive Execution of Late-Stage Clinical Programs and Extends its Operating Runway through Commercial Transition | Alignment Reached with U.S. FDA on Potential Accelerated Approval Pathway for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) Based on Biomarker Endpoints U.S. Biologics Licensing Application (BLA)... ► Artikel lesen | |
| BIODESIX | 8,080 | +47,99 % | Biodesix, Inc.: Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited) | Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025.... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,040 | -13,41 % | Summit Therapeutics Inc. - 8-K, Current Report | ||
| ARCUTIS BIOTHERAPEUTICS | 26,780 | -5,10 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children Ages 2 to 5 | Prescription Drug User Fee Act (PDUFA) target action date set for June 29, 2026If approved, ZORYVE cream 0.3% would be the first and only topical PDE4 inhibitor indicated for plaque psoriasis in children... ► Artikel lesen | |
| MONTE ROSA THERAPEUTICS | 23,720 | -2,43 % | Monte Rosa Therapeutics, Inc.: Monte Rosa Therapeutics Announces Pricing of $300 Million Underwritten Public Offering | BOSTON, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 32,980 | -1,17 % | Mineralys Therapeutics, Inc. - 8-K, Current Report | ||
| QIAGEN | 40,930 | -0,73 % | XFRA CAPITAL ADJUSTMENT INFORMATION - 07.01.2026 | Das Instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON EQUITY wird cum Kapitalmassnahme gehandelt am 07.01.2026 und ex Kapitalmassnahme am 08.01.2026 The instrument SFTU US83404D1090 SOFTBANK GR.UNS.ADR1/2/ON... ► Artikel lesen | |
| VERA THERAPEUTICS | 46,460 | -4,62 % | Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy | FDA assigned PDUFA target action date of July 7, 2026.If approved, atacicept would be the first B cell modulator targeting both BAFF and APRIL for IgAN.Atacicept received FDA Breakthrough Therapy... ► Artikel lesen | |
| ALUMIS | 21,090 | +7,82 % | Alumis Inc.: Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares | SOUTH SAN FRANCISCO, Calif., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing next-generation targeted therapies for patients with... ► Artikel lesen | |
| CG ONCOLOGY | 53,73 | -0,87 % | CG Oncology Inc.: CG Oncology Provides Updated Timeline for PIVOT-006 Phase 3 Topline Data in Intermediate-Risk NMIBC | - PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy for intermediate-risk NMIBC now expected in 1H 2026, nearly one year ahead of schedule - First randomized registrational trial... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 18,080 | -2,27 % | MoonLake Immunotherapeutics AG: MoonLake Immunotherapeutics Announces Positive Outcome from Type B Meeting with U.S. FDA and Announces Investor Day | MoonLake requested a Type B meeting with the U.S. Food and Drug Administration (FDA) to obtain regulatory clarity and discuss the clinical evidence strategy for submission of a Biologic License Application... ► Artikel lesen | |
| ADMA BIOLOGICS | 17,935 | -0,08 % | ADMA Biologics reports FY 2025 revenue in line with estimate, provides 2026-2029 outlook | ||
| APOGEE THERAPEUTICS | 77,65 | -0,51 % | Apogee Therapeutics Announces Positive Interim Results from Phase 1b Trial of Zumilokibart (APG777), its Potentially Best-in-Class Anti-IL-13 Antibody, in Patients with Mild-to-Moderate Asthma and Highlights 2026 Anticipated Milestones and ... | Phase 1b interim results of zumilokibart (APG777) in asthma demonstrated rapid and durable suppression of FeNO (key biomarker of Type 2 inflammation) through 16 weeks for all patients - Suppression... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 4,830 | +3,65 % | RECURSION PHARMACEUTICALS, INC. - 8-K, Current Report |
CURASIGHT A/S gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell +2,82 % bei einem Aktienkurs von 1,460 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CURASIGHT A/S finden Sie auf Wallstreet Online.